Concerns about the effectiveness of the Oxford University / AstraZeneca corona virus jab in the elderly Experts say different vaccines may be given to different ages.
The partners announced last week that the vaccine has an overall 70% effectiveness. For most test participants – given two full doses at one-month intervals – the efficacy was 62%, but if 3,000 participants were given the wrong half dose for their first jab, the efficacy was 90%. None of the participants, regardless of size, developed a severe goiter or were hospitalized with the disease.
U.S. There are regulators like the FDA Said before They will receive a vaccine that reduces the severity of the disease in at least 50% of those who are vaccinated or vaccinated.
The Oxford University / AstraZeneca results were very encouraging, with 90% of the performance competing with the vaccines of Moderna and Pfizer / Bioendech.
Unlike its competitors, the Oxford vaccine is inexpensive to produce and does not need to be stored at very cold temperatures. That too 100 m at 355 m Vaccine doses have early access to the UK government.
However, it has been revealed that none of the participants over the age of 55 were included in the low-dose group of the Oxford University / AstraZeneca vaccine, which means that it is unclear whether 90% of older people are at high risk. From Govt.
This led to AstraZeneca Announce a new global test The use of low-level regulations is not expected to affect the timeline for vaccine regulatory approval and release in the UK and Europe.
Professor David Salisbury, former Director of the Department of Immunology, speaking on BBC Radio 4’s Today Health, Said more tests are important.
“If this vaccine really comes to 90%, it requires a much less severe cold chain than the cheaper vaccine and the RNA vaccine. [from Moderna and Pfizer/BioNTech]That would be a great decision, “he said.
“But if it’s 62% and 90% of the other vaccines that have come so far, I think you have to think very carefully, what do we do with 100m of unprotected material as well as alternatives.”
That could lead to drastic results, he said. “I think it starts to give some sense of how you prioritize using your vaccines, and you may want to think about more effective vaccines for high-risk individuals where you want to protect them,” he said.
According to Helen Fletcher Guardian, professor of immunology at the London School of Hygiene and Tropical Medicine, AstraZeneca and Oxford are likely to be licensed for full-fledged rule, which protects 62% of the population from developing covit
“They have given high doses of immunizations to a large number of individuals, mainly the elderly who are at high risk for serious diseases,” he said. “Database for low-level regulation may not be sufficient to obtain a license, so it makes sense to do another test with a lower level – including older ones, and look for an amendment to use this size when they are sufficient. Information.”
But Fletcher agreed that it makes sense to look at all the vaccines available when it comes to immunization. “With so many vaccines available, I think it is right for policymakers to think about which vaccines may work best in which population,” he said. “This is not uncommon: we offer three types of flu vaccines in the UK for children, young people and the elderly, as we know that different vaccine sites work better for different ages.”
Dr. Benny Ward, a professor of pharmacology at King’s College London, said: “I personally see this. [Oxford/AstraZeneca] The vaccine (and other) is similar to the influenza vaccine – meaning they do not protect against infection, but reduce the severity of the disease and, more importantly, the risk of serious complications and death.
“It is important to note here that the influenza vaccine is 50-60% effective in most seasons, yet it reduces the severity of the disease and should be hospitalized in the vaccinated elderly population. It will be useful to help. “